SparingVision

This French startup is trying to find a cure for one of the most common forms of blindness, retinitis pigmentosa, which currently affects about two million people worldwide. SparingVision is focused on the development of an innovative gene therapy that will lead to the production of rod-derived cone-viability factor, a naturally occurring protein in the retina identified by startup’s co-founders.